EnteroBiotix

Partnering is OPEN for BIO International in San Diego, from June 3-6. Set up a meeting with our founder & CEO Dr James McIlroy at the largest event in #biotech now: https://lnkd.in/efSF-Aic Join us at a pivotal moment, having completed a £27m financing round and launched a phase 2 clinical trial of our lead product EBX-102-02, targeting Irritable Bowel Syndrome (#IBS), powered by our proprietary AMPLA™ technology. We’re redefining #microbiome therapeutics with our best-in-class full spectrum solution to resolve a clear unmet medical need and alleviate chronic symptoms for IBS patients. 🤝 Schedule a partnering meeting with James now: https://lnkd.in/efSF-Aic 🔗 Register for #BIO2024: https://lnkd.in/gSXh3GTj 🧑🔬 Learn how we’re mastering the microbiome: https://lnkd.in/gAph-nvk Biotechnology Innovation Organization #Pharma #Innovation #Partnering

A team of EBX staff from Production and Quality Assurance were very kindly offered the opportunity to visit Veranova’s Edinburgh site last week. Hosted by Susan McKenna and Jon Holley, the team were given a tour of their production facility and witnessed some great examples of lean manufacturing in action. Everyone was extremely impressed by what they saw and left with a vision of where these lean tools could benefit EBX. A great morning had by all 😀

Team EBX (Dr Karen Smith and Dr Rachel Donaghey) participated in a mini STEM day with children from a local primary school. During the event the children learned how EnteroBiotix is dedicated to developing novel treatments for life-threatening diseases, through modulation of the structure and function of the gut microbiome. Attendees participated in making their own ‘healthy microbiome’ using dried beans and pasta, which represent different types of bacteria that co-exist within the gut. The children learned about different ways scientists can identify the best stool donations to make microbiota-based medicines, they used the Bristol Stool Score to make their own models out of plasticine. Everyone, including the scientists, really enjoyed the event!

Join us at BioEquity Europe 2024 from 12-14 May in San Sebastian, where our CEO Dr James McIlroy is presenting. 📅May 14 | 11:30 – 11:45 | Room 9 | Microbiome Therapeutics: EnteroBiotix James will share insights on the latest milestones in our clinical development programs for our advanced full-spectrum microbial #therapeutics. We recently initiated a phase 2 clinical trial in Irritable Bowel Syndrome (#IBS) for our drug candidate EBX-102-02, powered by our proprietary AMPLA™ technology, and also successfully completed a significant £27m financing round. Join us to discover the future of #microbiome therapeutics to transform care for patients. 🤝Secure a 1-1 meeting with James: https://lnkd.in/eaw_6uwz 🔗 Join #BioEquity Europe 2024: https://lnkd.in/dzunkQc 🧑🔬 Learn how we’re mastering the microbiome: https://lnkd.in/gAph-nvk #Pharma #Biotech #Networking #Partnering #Investment #LifeSciences

💡 EnteroBiotix is pioneering a new field of science and medicine. Our company is made up of a diverse group of medical professionals, scientists, engineers, regulatory experts, pharmaceutical executives and business professionals that are united by a common sense of purpose: to unlock the therapeutic potential of the gut microbiome through novel microbiome modulating therapeutics.   We have some exciting open roles to join our passionate team, listed below:   🔹 Equipment and Facilities Engineer 🔹 Production Technologist 🔹 Quality Control Scientist (12-month FTC)   If you would like to have the opportunity to change the standard of care for patient populations suffering from hard-to-treat diseases and infections, please see the careers section of our website for more information and to apply: https://lnkd.in/dK4JiRz6   #hiringnow #lifesciences #biotech #biotechjobs #biotechcareers #opportunities #teamEBX

Request a partnering meeting with our founder and CEO Dr James McIlroy at the LSX World Congress on 29-30 April 2024 in London: 🤝https://lnkd.in/d8ZFmP5t Join James at the leading partnering, strategy and investment event in Europe, which gathers the founders and CEOs of the world’s most innovative #biopharma companies with key investors and industry KOLs. Hear about our cutting-edge full-spectrum microbial #therapeutics and gain insights into the latest advancements in our clinical development programs. Don’t miss the opportunity to connect with us following the recent success of our latest financing round and the initiation of a Phase 2 clinical trial for our drug candidate EBX-102-02 in Irritable Bowel Syndrome (#IBS), leveraging our proprietary AMPLA™ technology. 🤝 Schedule a partnering meeting: https://lnkd.in/d8ZFmP5t 🔗What’s happening this year at #LSXWorld - https://lnkd.in/ddbtpquX 🧑🔬 Learn how we’re mastering the microbiome: https://lnkd.in/gAph-nvk #partnering #investment #microbiome #lifesciences LSX - partnering for Life Science eXecutives

Join our founder and CEO Dr James McIlroy at BioTrinity on 24 April in London! Meet James at the OBN (UK) Ltd’s flagship conference for the #lifesciences industry to learn about our best-in-class full-spectrum microbial #therapeutics in clinical development. It’s the perfect time to connect as we have just successfully completed a significant financing round and initiated a phase 2 clinical trial in Irritable Bowel Syndrome (#IBS) for our drug candidate EBX-102-02, powered by our proprietary AMPLA™ technology. Support our mission to transform care for patients suffering from serious health conditions linked to a disrupted gut #microbiome. 📧 Contact us to schedule a meeting: partnering@enterobiotix.com 🧑🔬 Learn how we’re mastering the microbiome: https://lnkd.in/gAph-nvk #Pharma #Innovation

🔎 We are on the lookout for a passionate individual to join Team EBX 🔎   We have an exciting opportunity to join EnteroBiotix as an Equipment and Facilities Engineer, based in Glasgow. 👨🔬⚙   To find out more this exciting opportunity, as well as our comprehensive rewards and benefits package, use the following link: https://lnkd.in/eiRaY2GB   You would be joining a team of amazing people who are dedicated to making a difference. To find out more about who you would be working with, and life at EBX, visit our website: https://lnkd.in/e9tUFy8Q.   If you are interested, or know someone that might be, apply today on Indeed or by sending your CV to careers@enterobiotix.com!   #hiring #biotechcareers #engineering #openrole #glasgowjobs #glasgow #teamEBX

Today marks World Irritable Bowel Syndrome Day (#IBS), shedding light on a condition that affects millions worldwide, with symptoms including chronic abdominal pain, cramping, bloating, and change in bowel movements. It's not just about abdominal discomfort though; it's about the significant impact on every aspect of life. We're committed to making a difference, by developing best-in-class full-spectrum microbial therapeutics. We have a drug candidate in phase 2 clinical trials, EBX-102-02, powered by our proprietary AMPLA™ technology, which offers hope for those battling IBS. By fortifying and restoring the microbiome, our EBX-102-02 aims to resolve a clear unmet medical need and alleviate the chronic symptoms that disrupt daily life. Join us in raising awareness and supporting those affected by IBS, as we work towards a future where IBS no longer holds people back. #WorldIBSDay2024 #GutHealth #Biotech #Innovation 🔗www.worldibsday.com 🧑🔬 Learn how we’re mastering the microbiome: https://lnkd.in/gAph-nvk

📣We are excited to announce the successful completion of a £27m (USD 34m) financing round to advance our clinical trials. The round was led by experienced US-based life science investors Thairm Bio and Kineticos Life Sciences, and new investor The Scottish National Investment Bank, joining existing investors including Scottish Enterprise, and private investors. We thank them all for supporting our vision to transform the standard of care for patients suffering from serious health conditions linked to a disrupted gut microbiome. This follows hot on the heels of yesterday’s news announcing the dosing of our first patient in a Phase 2 Study of EBX-102-02 in Irritable Bowel Syndrome (#IBS) in collaboration with the Functional Gut Clinic. 🔗 Read our press release: https://lnkd.in/eqar79nj 🧑🔬 Learn how we are mastering the microbiome: https://lnkd.in/gAph-nvk #Biotech #LifeSciences #GutHealth #financing Dr James McIlroy